Charles Alpers, MD, is a professor and Vice Chair of Pathology, Adjunct Professor of Medicine, and Director of Renal Pathology at the University of Washington Medical Center. He is the Pathology Editor for the Clinical Journal of the American Society of Nephrology (CJASN) and has served as the Associate Editor for the American Journal of Pathology and the Journal of the American Society of Nephrology.
Consultant: Amgen; Eli Lilly and Company; Genentech,
Wyeth Pharmaceuticals
Grant/research support: Genzyme
Roy D Bloom, MD, is an associate professor of Medicine and the Medical Director of the Kidney/Pancreas Transplant Program at the University of Pennsylvania. His particular interests are complications and outcomes of HCV infection in kidney transplantation. In 2005, Dr Bloom was honored with the AST/Wyeth Clinical Science Career Development Award.
Consultant: Novartis
Speaker: Astellas Pharma Inc.
Fabrizio Fabrizi, MD, is a nephrologist at Maggiore Hospital, IRCCS, Milano, Italy. He is also a research associate in the Division of Liver Diseases, Mount Sinai School of Medicine, New York City, NY, USA. His research interests include HBVand HCV in CKD patients. He has received several grants from the Italian Society of Nephrology and the Society of Italian-American Nephrologists. Dr Fabrizi serves on the editorial board of the International Journal of Artificial Organs and Journal of Nephrology. He has authored numerous publications for the American Journal of Transplantation, American Journal of Kidney Diseases, and Nephrology Dialysis Transplantation, among others.
Dr Fabrizi reported no relevant financial relationships.
Jacques Izopet, MD, is a professor of Medicine and practicing physician at Centre Hospitalier Universitaire (CHU) de Toulouse in France. He has contributed to various academic journals such as the Journal of Acquired Immune Deficiency Syndromes,
Transplantation, Journal of Virology, and Néphrologie & Thérapeutique. In addition, he is involved with the Agence Nationale de Recherche sur le Sida et les hépatitis virales (ANRS), France's National Agency for AIDS and viral hepatitis research.
Consultant: Abbott; Beckman Coulter; GMED/LNE;
Roche Diagnostics
Speaker: Abbott; Boehringer Ingelheim; Gilead Sciences
Inc.; Roche
Grant/Research Support: Roche
Michel Jadoul, MD (Work Group Co-Chair), is Head of the Department of Nephrology at Cliniques Universitaires Saint-Luc and Clinical Professor of Medicine at the Université Catholique de Louvain, both in Brussels, Belgium. He is an associate editor of the American Journal of Kidney Diseases and a member of the editorial board of Nephrology Dialysis Transplantation and Clinical Nephrology. He is also a country investigator for the Dialysis Outcomes and Practice Patterns (DOPPS) study. His research interests include the epidemiology of hepatitis C in hemodialysis, including nosocomial transmission, b2-microglobulin amyloidosis, and the epidemiology of falls and bone fractures in hemodialyzed patients.
Grant/research support: Amgen
Elizabeth Lindley, PhD, is a clinical scientist in Renal Care at the Leeds Teaching Hospital NHS Trust in the United
Kingdom. Dr Lindley has served with the European Dialysis and Transplant Nurses Association/European Renal Care Association (EDTNA/ERCA) as Research Board Chair and Journal Club Moderator. She has a special interest in continuous quality improvement, dialysis adequacy, and management of renal anemia and bone disease.
Speaker: Amgen; Gambro
Paul Martin, MD, is a professor of Medicine at the Mount Sinai School of Medicine, and is the Associate Director of the Division of Liver Diseases. He completed his fellowship in the Liver Unit at the National Institutes of Health (NIH) from 1987 to 1989, and his special interests include studying the natural history of HCV in CKD. He is currently a board member for the American Liver Foundation.
Consultant: Roche
Speaker: Roche
Grant/research support: Roche
José M Morales, MD, is an associate professor of Medicine in the Renal Transplant Unit, Department of Nephrology,
at Hospital 12 de Octubre in Madrid, Spain, and a member of the Expert Group of European Best Practice Guidelines. He has written for the Journal of the American Society of Nephrology, Journal of Hypertension, and most recently, Blood Purification. Dr Morales has been the Principal Investigator on studies concerning HCV and kidney transplantation, cholesterol crystal embolization, and immunosuppressive combinations on arterial hypertension after kidney transplantation.
Consultant: Astellas Pharma Inc.; Novartis; Wyeth Pharmaceuticals
Speaker: Astellas Pharma Inc.; Novartis;Wyeth Pharmaceuticals
Svetlozar Natov, MD, is the Chief Medical Officer/ Medical Director of Kindred Hospital Northeast at Braintree,
Natick, Stoughton, and Waltham, MA, USA, and is the President and co-owner of Natov Medical Associates, P.C. He is a staff nephrologist at South Shore Hospital in Weymouth, MA, USA, and Caritas Saint Elizabeth Medical Center in Boston, MA, USA.
Dr Natov reported no relevant financial relationships.
Stanislas Pol, MD, PhD, is a professor of Hepatology and Gastroenterology affiliated with Ho^ pital Cochin in Paris,
France. He has addressed issues involving hepatitis C virus in Nephrology Dialysis Transplantation, The Journal of Infectious Diseases, and Seminars in Nephrology.
Consultant: Boehringer Ingelheim; Bristol-Myers Squibb;
Gilead Sciences, Inc.; Roche; Schering-Plough
Speaker: Boehringer Ingelheim; Bristol-Myers Squibb;
Gilead Sciences, Inc.; Roche; Schering-Plough
Grant/research support: ANRS; Gilead Sciences Inc.;
Roche; INSERM; Schering-Plough
K Rajender Reddy, MD, is a professor of Medicine and Surgery with the University of Pennsylvania Health System (UPHS) in Philadelphia. In addition, he is the Director of Hepatology at the UPHS Division of Gastroenterology, and Medical Overseer of Liver Transplantation in Penn Transplant Institute-Liver Transplant.
Dr Reddy reported no relevant financial relationships
Lionel Rostaing, MD, PhD, is affiliated with the Multi- Organ Transplant Unit and is a professor of Nephrology at
Centre Hospitalier Universitaire (CHU) de Toulouse in France. His research interests are HCV and HBV infection in dialysis and kidney transplant patients, infectious complications after organ transplantation, and monitoring of immunosuppressive drugs.
Dr Rostaing reported no relevant financial relationships.
David Roth, MD (Work Group Co-Chair), is a professor of Medicine and Chief of the Division of Nephrology and Hypertension at the University of Miami School of Medicine. He completed his training at Jackson Memorial Hospital and the University of Miami, and is board-certified in both Internal Medicine and Nephrology. His research interests include kidney transplantation and HCV.
Dr Roth reported no relevant financial relationships.
Lai Wei, MD, PhD, is Professor and Director of the Hepatology Institute at Peking University People's Hospital in Beijing. His special interests include studying the natural history and replication of HCV and the means for testing its presence. Dr Wei was awarded the National Scientific and Technological Achievement of China. He has received research funds from the National Natural Scientific Foundation of China and has served as the Principal Investigator for trials with the National Science and Technology Key Study Plan of China.
Dr Wei reported no relevant financial relationships
LIASIONS
Miriam Alter, MD, is a faculty member at the University of Texas Medical Branch in the Departments of Internal
Medicine and Preventive Medicine, and she was recently awarded the Robert E Shope Distinguished Professorship in Infectious Disease Epidemiology. She is currently affiliated with the American Association for the Study of Liver Diseases, the Infectious Diseases Society of America, and the Society for Health Care Epidemiologists of America. Dr Alter is also involved with the Society for Epidemiologic Research, the American Association of Blood Banks, the American Epidemiological Society, and is an Editorial Advisory Board member for Dialysis and Transplantation. She previously held an appointment at the Centers for Disease Control and Prevention (CDC).
Dr Alter reported no relevant financial relationships .
Daniel Lavanchy, MD, is affiliated with the World Health Organization (WHO) in the Department of Communicable
Disease Surveillance and Response (CSR). He is an advisor for their Viral Hepatitis Prevention Board and has a special interest in public health.
Dr Lavanchy reported no relevant financial relationships.
Catherine Meyers, MD, is Director of the Inflammatory Renal Diseases Program with NIH/NIDDK (National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases). She is a former faculty member of the University of Pennsylvania and a Fellow of the American Heart Association. Dr Meyers serves on the boards for the Kidney Council for the American Heart Association and the Transplantation Research Coordinating Committee for the National Institutes of Health. She is certified in both Internal Medicine and Nephrology. Dr Meyers is currently associated with Dialysis Access Consortium trials of AVF and AVG for hemodialysis, and the Consortium for Radiologic Imaging Studies of PKD.
Dr Meyers reported no relevant financial relationships.
Leonard Seeff, MD, is a senior scientist for Hepatitis Research with the National Institutes of Health (NIH) where
he has also served on various boards concerning NIH and Food and Drug Administration (FDA) interrelations. He was Chief of Gastroenterology and Hepatology at the VA Medical Center and a professor of Medicine at Georgetown University. Dr Seeff is also affiliated with the American Association for the Study of Liver Diseases. He has special interests in viral hepatitis, particularly HCV, as well as in drug-related liver diseases.
Dr Seeff reported no relevant financial relationships.
KDIGO CO-CHAIRS
Garabed Eknoyan, MD, is a professor of Medicine, Section of Nephrology, at Baylor College of Medicine in Houston, TX,
USA. After earning his medical degree from the American University of Beirut, he completed residency at Baylor University Medical Center and fellowship at the University of Texas-Southwestern Medical School in Dallas. He has authored numerous publications in prominent journals during his career. Dr Eknoyan's clinical and research interests include acute and chronic renal failure, hemodialysis, and the history of nephrology.
Dr Eknoyan reported no relevant financial relationships.
Norbert Lameire, MD, is a professor of Medicine at the Institute for Nephrology at Ghent University Hospital in
Belgium. He is a committee member on the ERA/EDTA Council and is the current Editor-in-Chief for Nephrology Dialysis Transplantation. He was honored with the Bywaters Award by the International Society of Nephrology (ISN), and also received an Honorary Award from the National Kidney Foundation (USA) in 2007.
Speaker: Fresenius Medical Care; GE Healthcare; Roche
EVIDENCE REVIEW TEAM
Ethan Balk, MD, MPH, is an assistant professor of Medicine at Tufts University and the Associate Program Director,
Evidence-Based Medicine, National Kidney Foundation (NKF) Center for Clinical Practice Guideline (CPG) Development and Implementation at Tufts-New England Medical Center in Boston, MA, USA. Dr Balk completed a fellowship in Clinical Care Research. His primary research interests are evidence-based medicine, systematic review, CPG development, and critical literature appraisal.
Dr Balk reported no relevant financial relationships.
Jonathan Craig, MBChB, FRACP, PhD, is an associate professor at the University of Sydney's School of Public Health, a senior staff specialist in Pediatric Nephrology at the Children's Hospital at Westmead, and Head of the Centre for Kidney Research at the Children's Hospital at Westmead, Australia. He began his current appointment as the Coordinating Editor of the Cochrane Renal Group in 2000, and has cultivated his research interests in randomized controlled trials, systematic reviews, and diagnostic test evaluation, applied to a variety of kidney areas. He has served on many editorial boards, including American Journal of Kidney Diseases, Journal of the American Society of Nephrology, and Nephrology. Dr Craig has authored over 150 articles, including publications in the Lancet, The New England Journal of Medicine, Annals of Internal Medicine, and the British Medical Journal.
Dr Craig reported no relevant financial relationships.
Amy Earley, BS, is a research assistant at the NKF Center for CPG Development and Implementation at Tufts-New England Medical Center in Boston, MA, USA. She assists in the development of evidence-based clinical guidelines and conducts systematic reviews and critical literature appraisals. Ms Earley reported no relevant financial relationships. Craig Gordon, MD, MS, is currently a clinical fellow in the Division of Nephrology at Tufts-New England Medical Center. He was a research fellow in the NKF Center for CPG Development and Implementation from 2005 to 2007. His research interests include examining treatments of hepatitis C virus in hemodialysis patients through systematic review and meta-analysis.
Consultant: Advanced Magnetics Inc.
John Ioannidis, MD, is a professor and the Chairman of the Department of Hygiene and Epidemiology at the University
of Ioannina School of Medicine, and is affiliated with the Biomedical Research Institute-Foundation for Research and Technology-Hellas, both in Ioannina, Greece. He is also an adjunct professor within the Department of Medicine at Tufts- New EnglandMedical Center in Boston,MA, USA. Dr Ioannidis has authored over 300 peer-reviewed articles and is a member of the editorial board for 17 international journals. His interests include evidence-based medicine, clinical and molecular epidemiology, mathematical modeling, and public health.
Dr Ioannidis reported no relevant financial relationships. |
